Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
STW5 · 2 trials · 2 indications
The pain intensity is documented on a 10 cm visual analogue scale (VAS) scale
Area under the curve (AUC) of patients' assessment of gastrointestinal symptoms evaluated by daily visual analogue scale (VAS)
| Arm | Type | Description |
|---|---|---|
| STW5 | EXPERIMENTAL | 2/3 patients with irritable bowel syndrome will be randomized in this arm |
| Placebo | PLACEBO_COMPARATOR | 1/3 patients with irritable bowel syndrome will be randomized in this arm |
| STW5 (Iberogast®, BAY98-7411) | EXPERIMENTAL | The medication was applied daily per os (orally, p.o.) from day 0 to day 28. The dosage was 20 drops three times daily before the meals. |
| Name | Type | Description |
|---|---|---|
| STW5 (Iberogast, BAY98-7411) | DRUG | Applied orally over 28 days, 20 drops STW 5 three times daily |
| Placebo | DRUG | Applied orally over 28 days, 20 drops placebo three times daily |
| STW5 (Iberogast®, BAY98-7411) | DRUG | The medication was applied daily per os (orally, p.o.) from day 0 to day 28. The dosage was 20 drops three times daily before the meals. |
Inclusion Criteria: * Patients of either sex aged \>18 years * Patients meeting the Rome III irritable bowel syndrome (IBS) diagnostic criteria. IBS is defined as recurrent abdominal pain or discomfort at least 3 days/month in last 3 months (onset at least 6 months ago) associated with two or more ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 2 | PHASE3 | Eluxadoline |
| Ardelyx, Inc. | ARDX | 3 | PHASE3 | Tenapanor |
| Disc Medicine, Inc. | IRON | 1 | PHASE2 | DISC-0974 |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 2 | - | Undisclosed |
| Johnson & Johnson | JNJ | 1 | - | Anti TNF therapy including infliximab, No Biologics |
| Cooper Companies, Inc. | COO | 1 | N/A | Undisclosed |
STW5 is an investigational small molecule being developed for functional gastrointestinal disorders and irritable bowel syndrome. It is a plant-based combination product being studied for its effects on digestive symptoms. The drug is currently in clinical development and has not been approved by regulatory authorities.
STW5 is being developed by Bayer AG, a multinational pharmaceutical company traded on the OTC market under the ticker BAYRY. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with gastrointestinal conditions.
STW5 is in Phase 2 clinical development. The drug has completed one Phase 2 trial and one Phase 3 trial, both in Germany. It remains investigational and has not received regulatory approval for any indication.
STW5 has been studied in two completed clinical trials. NCT01940848 was a Phase 3 study in 243 patients with irritable bowel syndrome, and NCT04059900 was a Phase 2 study in 64 patients with functional gastrointestinal disorders. Both trials were conducted in Germany.
STW5 is the active ingredient in Iberogast, a commercial product. The clinical trial NCT01940848 was designed to confirm Iberogast's efficacy in patients with irritable bowel syndrome. STW5 is the pharmaceutical name used in clinical research for this combination product.